NewsBenzingaHC Wainwright & Co. 重申对 Beam Therapeutics 的“买入”评级，维持 80 美元目标价 HC Wainwright & Co. 重申对 Beam Therapeutics 的“买入”评级，维持 80 美元目标价 Benzinga 2026.10.15 10:14 (GMT+0) Open on Benzinga Other news Susquehanna Maintains Positive on United Airlines Holdings, Lowers Price Target to $130 Susquehanna Maintains Positive on Meta Platforms, Raises Price Target to $850 Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients Susquehanna Maintains Neutral on IBM, Raises Price Target to $256 Susquehanna Maintains Neutral on Genpact, Raises Price Target to $40 Keybanc Maintains Overweight on Meta Platforms, Raises Price Target to $905
Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients
